Month: August 2021

STRATHROY, Ontario, Aug. 18, 2021 (GLOBE NEWSWIRE) — Eve & Co Incorporated (“Eve & Co”, “we”, “us” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF), is pleased to announce that its wholly-owned subsidiary, Natural MedCo Ltd. (“NMC”) has successfully entered into a Medical Cannabis Supply and Purchase Agreement (the “Agreement”) with TCann Pty Ltd., Australia (“TCann”), an import/export and distribution company of para-pharmaceutical, medicinal and narcotic products located in Thornleigh, New South Wales. Pursuant to the Agreement, NMC will supply medical grade dried cannabis flower to TCann and TCann will distribute NMC medical grade dried cannabis products in Australia. TCann is a licensed cultivator and manufacturer of medicinal cannabis products. TCann focuses on producing high quality pharmaceutical-grade cannabis products...

Agreement allowing work on numerous collaborative research initiatives in the coming years DENVER, Aug. 18, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) announces it has signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine, with research to be led by Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University, Dr. Matthew W. Johnson, Ph. D. The Johns Hopkins Behavioral Pharmacology Research Unit has extensive experience conducting clinical research related to therapeutic use of psychedelics.   Mydecine CEO Josh Bartch said, “We are excited to expand on the current work we are conducting with Dr. Matt Johnson and his team at JHU in regards to smoking cessation to include numerous other projects over the next five years. The researchers at JHU...

GOODMIND™Psyence Group Announces the Commencement of Online Sales and Distribution of “GOODMIND” ProductsTORONTO and CAPE TOWN, South Africa, Aug. 18, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce the commencement of online sales and distribution of its premium range of functional mushroom products, GOODMIND™. The GOODMIND™ formulas harness the power of adaptogens; non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress. Psyence has partnered with...

Baltic Horizon Fund invites unitholders, investors, analysts and other stakeholders to join its investor conference webinar, scheduled on 26 August 2021 at 13:00 PM (CET) or 14:00 PM (EET). The webinar will be hosted by Tarmo Karotam, the Fund Manager of Baltic Horizon Fund. Q&A session will follow after the presentation. Due to limited webinar time, we encourage participants to send their questions no later than one day before the webinar to tarmo.karotam@nh-cap.com. To join the webinar, please register via the following link:  https://register.gotowebinar.com/register/3139815299395792397 You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can’t be downloaded,...

Completed the regulatory process required to ship medical cannabis to Brazil with import permits issued from ANVISA and export permits issued from Health Canada. Initial deliveries will be under the compassionate care program. First shipments to Brazil to be used for patient trials to collect data that may be used in future product marketing authorizations under Brazil’s medical cannabis program. A program that saw over 20,000 patients in 2020 and is growing by 1,500 patients a month.BARRIE, Ontario, Aug. 18, 2021 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company that specializes in cannabis, is pleased to announce that it has received approval to ship medical cannabis oil to Brazil. This approval, issued by both ANVISA and Health Canada,...

Figure 1Wabash property – June 2021 grab samples resultsMONTREAL, Aug. 18, 2021 (GLOBE NEWSWIRE) — Kintavar Exploration Inc. (the “Corporation” or “Kintavar”) (TSX-V: KTR), is very pleased to announce the results from the trenching in the Indiana area where mineralization was earlier discovered in the summer. The three trenches in the Indiana area are along strike and extend over 500m with mineralization observed within interbedded metric calcitic marbles and paragneissic units. The major sulfides associated with the mineralization are chalcopyrite, bornite-covellite, sphalerite and galena which are all indicative of additional enrichment patterns within the stratiform copper sequence. The Corporation is working with its technical advisor Dr. Michel Gauthier define the controls of the mineralized system and develop...

Baltic Horizon Fund invites unitholders, investors, analysts and other stakeholders to join its investor conference webinar, scheduled on 26 August 2021 at 13:00 PM (CET) or 14:00 PM (EET). The webinar will be hosted by Tarmo Karotam, the Fund Manager of Baltic Horizon Fund. Q&A session will follow after the presentation. Due to limited webinar time, we encourage participants to send their questions no later than one day before the webinar to tarmo.karotam@nh-cap.com. To join the webinar, please register via the following link:  https://register.gotowebinar.com/register/3139815299395792397 You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can’t be downloaded,...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc.  (“ProMIS” or the “Company”) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce the pricing of its previously announced public offering (the “Offering”). Pursuant to the Offering, the Company will issue up to 93,750,000 units (the “Units”) at a price of US$0.16 per Unit (the “Issue Price”) for aggregate gross proceeds of US$15 million, exclusive of the Agent’s Option (as defined herein) and before deducting the Agent’s Cash Commission (as defined herein) and estimated Offering expenses payable by the Company. Each Unit...

An Emerging Markets Sponsored Commentary ORLANDO, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) — Breaking news from Mobilum Technologies Inc. (CSE: MBLM) (OTC: MBLMF) (FRA: C0B) may turn the heads of those fervently watching the crypto community. Mobilum, which describes itself as “a technology driven payment service provider company with a mission to make traditional finance accessible through compliant digital payment infrastructure and digital asset management technologies” just announced that it has signed an agreement with ALT 5 Sigma (“ALT 5”) to provide fiat-credit-cards-to-crypto on-ramp services to its users on Alt5Coins.com. Note the following! First, let’s establish for the uninitiated what “fiat” means. Fiat, by conventional definition is “government-issued currency that is not backed by a physical commodity, such...

MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpoints Study data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary endpoint 20-patient study suggests combination therapy may benefit cystic fibrosis patients with severe EPIBOCA RATON, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced positive topline results from its Phase 2 Combination Trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis (CF). Data...